ATYPICAL CLINICAL COURSE OF FXTAS: RAPIDLY PROGRESSIVE DEMENTIA AS THE MAJOR SYMPTOM
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The fragile X–associated tremor/ataxia syndrome (FXTAS) is a progressive neurologic disorder that may affect carriers of premutations of the FMR1 gene (55 to 200 CGG repeats), mainly men older than 50 years of age. These individuals do not have the mental retardation syndrome, which is caused by the FMR1 gene full mutation (>200 CGG repeats). The major FXTAS features include progressive intention tremor and cerebellar ataxia, often accompanied by progressive cognitive and behavioral disturbances, such as memory loss, anxiety, deficits of executive functions, and reclusive or irritable behavior, with a gradual appearance of dementia in some individuals; parkinsonism, peripheral neuropathy, lower-limb proximal muscle weakness, and autonomic dysfunction may be present.1 Severe dementia has been seen in a limited number of patients.2 Neuropsychological assessments in 29 FXTAS patients revealed that 21% had Full Scale IQs <85, reflecting severe cognitive impairment or dementia.3 Neuropsychiatric manifestations (agitation/aggression, depression, apathy, disinhibition, and irritability) compatible with frontal-subcortical dementia were documented as significantly greater in patients with FXTAS vs normal age-matched controls.4 …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS)J. S. Adams, P. E. Adams, D. Nguyen et al.Neurology, August 27, 2007 -
Article
White matter disease and cognitive impairment in FMR1 premutation carriersChristopher M. Filley, Mark S. Brown, Karen Onderko et al.Neurology, April 29, 2015 -
Articles
FMR1 CGG repeat length predicts motor dysfunction in premutation carriersM. A. Leehey, E. Berry-Kravis, C. G. Goetz et al.Neurology, December 05, 2007 -
Brief Communications
Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS)D. A. Hall, E. Berry-Kravis, S. Jacquemont et al.Neurology, July 25, 2005